Marc Tessier-Lavigne's father, a Canadian military officer, was posted to London and then Brussels with the NATO delegation.
“he was eventually sent to Europe, to London, and then Brussels with the NATO delegation out there.”
Person
Marc Tessier-Lavigne is a neuroscientist and drug-industry leader who appears in a podcast conversation about his career and about using AI to reinvent drug discovery. On The Long Run with Luke Timmerman, he covered his path from physics at McGill to Oxford and University College London, then a faculty post at UCSF in 1991.
He also discussed joining Genentech in 2003, co-founding Denali Therapeutics in 2015, and his time as Stanford's president. He described how Xaira, a company built on AI protein and antibody design, works. He cited about 13 years on average from target to FDA approval, with only about one in ten clinical drugs succeeding.
1 episodes · 24 quoted claims
Marc Tessier-Lavigne's father, a Canadian military officer, was posted to London and then Brussels with the NATO delegation.
“he was eventually sent to Europe, to London, and then Brussels with the NATO delegation out there.”
Marc Tessier-Lavigne went to Oxford on a Rhodes Scholarship after studying physics at McGill.
“I was fortunate to get a scholarship, a Rhodes Scholarship, to go to Oxford.”
At Oxford, Marc Tessier-Lavigne earned a second undergraduate degree in physiology and philosophy, where the physiology covered neuroscience and biochemistry.
“So I did a degree in physiology and philosophy, and the physiology was neuroscience and biochemistry.”
Marc Tessier-Lavigne did his PhD at University College London under David Attwell, as Attwell's first PhD student.
“I followed David to do my PhD with him as his first PhD student.”
Marc Tessier-Lavigne took his first faculty position, at UCSF, in 1991.
“So I took my first faculty position in 1991.”
Tessier-Lavigne's lab identified some of the first chemoattractant factors that guide axons in the brain, which it named netrins.
“we were fortunate to identify some of the first chemotractants in the brain, which we called netrons”
Early in his lab's work, Tessier-Lavigne was funded in part by the Paralyzed Veterans of America spinal cord research foundation.
“one of my funding sources was the paralyzed veterans of america spinal cord research foundation”
When he joined Genentech in 2003, Tessier-Lavigne oversaw about two-thirds of the research portfolio, including oncology.
“I was brought in to oversee about two-thirds of the research portfolio, including oncology”
Genentech, which had spun out its earlier neuroscience work, rebuilt a neurodegeneration research group during Tessier-Lavigne's tenure.
“So we actually built back up a neuro group at Genentech.”
Denali Therapeutics was co-founded in 2015 by Marc Tessier-Lavigne with Ryan Watts and Alex Schuth, encouraged by Bob Nelson.
“Bob encouraged me as well as two colleagues from Genentech, Ryan Watts and Alex Shuth, to co-found Denali in 2015.”
After leaving Genentech, Tessier-Lavigne joined the boards of Pfizer and Regeneron.
“I also joined two larger companies, the boards of Pfizer and Regeneron.”
During Tessier-Lavigne's presidency, Stanford University opened its first new school in 75 years, the School of Sustainability.
“including opening Stanford's first new school in 75 years, the School of Sustainability”
After leaving Stanford, Marc Tessier-Lavigne was contacted by Bob Nelson about a company idea with Vic Bajaj and David Baker that became Xaira.
“I pretty rapidly got a call from none other than Bob Nelson, who told me about this exciting idea that he and Vic Bajaj and David Baker were working on”
Tessier-Lavigne describes drug discovery as choosing a target, making a drug that acts on it, and identifying patients likely to respond.
“if you think about the drug discovery process, you have to choose a target. You have to make the drug that has the intended effect on the target.”
David Baker's lab published RFdiffusion in 2023 and RFantibody in 2024, generative AI tools for designing proteins and antibodies.
“David's advances with generative AI with RF diffusion in 2023 and RF antibody in 2024.”
Protein-design models are trained in large part on the curated structures in the Protein Data Bank.
“The data that forms the foundation of that is the highly curated data in the protein data bank, the PED.”
Xaira says it makes millions of AI designs and tests hundreds of thousands of them in the lab, feeding results back to its models.
“making millions of designs, testing hundreds of thousands of them in the wet lab in these virtual cycles”
Xaira is first applying AI antibody design to hard-to-drug targets such as multi-pass membrane proteins, which have little surface exposed outside the cell.
“Think multi-pass membrane proteins with small amounts of real estate on the outside of the cell”
scGPT, an early single-cell foundation model, was created by Bo Wang, who now works at Xaira.
“single cell GPT, SCGPT, created by Bo Lang, who's now here at Xaira, for example, very powerful”
Perturb-seq inactivates one gene at a time and measures the effect on all roughly 20,000 genes in the cell.
“one gene at a time, you modify the gene, you inactivate the gene, look at the effect on all 20 ,000 genes in the cell.”
In June, Xaira published a methods paper and what it described as the largest Perturb-seq datasets to date, from two cell lines.
“We just, back in June, published the largest PerturbSeq datasets to date”
Xaira's released Perturb-seq data was downloaded about 64,000 times in three months.
“there have been, I think now, 64 ,000 downloads of the data in just three months.”
Xaira has a sizable site in Seattle near David Baker's lab, alongside its South San Francisco headquarters and a small London group.
“We have a sizable site in Seattle near in proximity to David Baker's lab.”
Tessier-Lavigne cites about 13 years on average from target to FDA approval, with only about one in ten clinical drugs succeeding.
“it's 13 years on average to go from having a target, making the drug and getting it through clinical trials to FDA approval”